Objective: This paper aims to discuss the clinical effects of therapy with a combination of valsartan and metoprolol on elder patients with acute myocardial infarction and fatal arrhythmia.
Methods: A total of 78 cases of acute myocardial infarction and foetal arrhythmia registered in our hospital from October 2015 to 2016 were selected and divided into the control group and observation group randomly according to the double-blind random principle. A total of 39 cases were included in each group. The control group received metoprolol only, whereas the observation group was treated with the combination of metoprolol and valsartan. Clinical effects of these treatments on the two groups were compared.
Results: The observation group is superior to the control group in terms of the total therapeutic efficiency, incidence of ventricular fibrillation, and death rate, and the difference was significant (P<0.05). The Left Ventricular Ejection Fraction (LVEF) and average stay of the observation group were better than those of the control group, and the difference was significant (P<0.05). Before the treatment, the two groups had similar PICP, PCIII, MMP-1 and TIMP-1 (P>0.05). After the treatment, PICP, PCIII, and MMP-1 of the observation group were significantly lower than those of the control group (P<0.05). However, the TIMP-1 of the observation group is significantly higher than that of the control group (P<0.05). The control group shows much higher incidence of complications and death rates compared with the observation groups (P<0.05).
Conclusions: The combined therapy of valsartan and metoprolol shows high safety and satisfying clinical effect when used on elder patients with acute myocardial infarction and fatal arrhythmia. This treatment is worth extensive promotion.Author(s): Yong-Zhong Mao, Ling Jiang